Sign in to confirm you’re not a bot
This helps protect our community. Learn more

Tryp Therapeutics new CEO looking to take big steps this year with a number of partnerships

Proactive Investors
61.9K subscribers
228 views 4 years ago
Tryp Therapeutics (CSE: TRYP- OTCQB: TRYPF) CEO Greg McKee joined Steve Darling from Proactive to talk about his new role as Chairman and CEO. McKee talks about his background and what he sees moving forward for the company. McKee telling Proactive about some of their drugs in the pipeline and how close they are to clinical trial stage. This include Psilocybin-for-Neuropsychiatric Disorders targeting chronic pain and eating disorders. We also get an update on razoxane with his designed for soft tissue sarcomas. ...more
...more
Tryp Therapeutics new CEO looking to take big steps this year with a number of partnerships
N/ALikes
228Views
2021May 3
Tryp Therapeutics (CSE: TRYP- OTCQB: TRYPF) CEO Greg McKee joined Steve Darling from Proactive to talk about his new role as Chairman and CEO. McKee talks about his background and what he sees moving forward for the company. McKee telling Proactive about some of their drugs in the pipeline and how close they are to clinical trial stage. This include Psilocybin-for-Neuropsychiatric Disorders targeting chronic pain and eating disorders. We also get an update on razoxane with his designed for soft tissue sarcomas.

Proactive Investors

61.9K subscribers